TU2218

Latest Posts

TU2218 is a probably first-in-class twin inhibitor focusing on reworking progress issue beta receptor...

Market

TiumBio Declares First Affected person Dosed in Section 2 Scientific Trial of Oral Immuno-Oncology Drug TU2218 By Investing.com